Novo Nordisk NOVO.B1.08%increase; green up pointing triangle filed for U.S. Food and Drug Administration approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Join us Jan. 14 for a virtual discussion about our Rx ...

Pfizer Inc. pulled off a comeback win, beating out Danish drug giant Novo Nordisk to acquire obesity drug developer Metsera Inc. in a deal that values the biotechnology company at up to $9.1 billion.

A drug maker is looking for participants for a clinical trial involving an investigational Alzheimer's drug, and Baltimore is one of the trial locations.The purpose of Merck's study is to see if the ...

Eli Lilly and Company says the highest doses of its next-generation weight loss drug helped patients lose an average of 28.7 percent of their body weight in a new study, significantly more than its ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

A New Jersey drug maker is voluntarily recalling thousands of bottles of a prescription drug used to treat hypertension after discovering it could be cross-contaminated with another drug, The Hill ...

Thousands of bottles of a commonly used prescription drug to treat hypertension has been recalled for possible contamination with another drug. The global drug maker, which is headquartered in Mumbai, ...

You can spot it even from across the room. The difference between something made with care and something made for numbers. One feels personal, the other feels printed. That difference is what’s ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

A federal judge in Pennsylvania has approved a nearly $60 million settlement with a trio of drug makers who are defendants in a multi-district litigation claiming numerous companies fixed the prices ...